Skip to main content
Premium Trial:

Request an Annual Quote

Patrick Sullivan, David Smoller, Rainer Voegeli, James Green, Michael Mullenix, Gabriella Szekely-Klepser

Sigma-Aldrich last week named Patrick Sullivan vice president of R&D for the research biotech business unit. His appointment became effective Oct. 1. In his position, he will “help expand Sigma-Aldrich’s leadership position through the development of new and innovative products for life science researchers,” the company said in a statement. He will report to David Smoller, the company’s president of research biotech.
Since 2005 Sullivan has been on Sigma-Aldrich’s scientific advisory board. Most recently, he was with Pfizer where he was involved in identifying new therapies for osteoarthritis and cardiovascular diseases. He has also held positions with Incyte Genomics and Monsanto/Searle/Pharmacia.

Rainer Voegeli joined Proteome Sciences in August as commercial director, the company said last week. Voegeli was previously at BioVision where he served as chief business officer. The previous commercial director, James Green, retired. He resigned as a company director on Oct. 2.

Michael Mullenix and Gabriella Szekely-Klepser have joined Assay Designs as vice president of R&D, and vice president, science and technology, respectively, the company said this week.
Mullenix was previously at Amgen as a principal scientist in its clinical immunology group. He oversaw a team that worked on developing GLP-compliant immunoassays. Prior to Amgen he held R&D positions with Molecular Staging, Becton Dickinson, and Strategic Diagnostics.
Szekely-Klepser was previously an associate research fellow at Pfizer Global R&D where she led the translational research biomarker implementation and biologics bioanalytical groups. She also held R&D positions at 3M.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.